Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04947189
Registration number
NCT04947189
Ethics application status
Date submitted
25/03/2021
Date registered
1/07/2021
Date last updated
16/10/2023
Titles & IDs
Public title
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
Query!
Scientific title
4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer
Query!
Secondary ID [1]
0
0
4CAST
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
4CAST
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Triple Negative Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Seviteronel-D (Seivteronel in combination with dexamethasone)
Treatment: Drugs - Docetaxel
Experimental: Seviteronel, dexamethasone and docetaxel - Part 1: Seviteronel will be administered orally beginning with 450 mg (3 x 150 mg tablets) once daily along with 0.5 mg dexamethasone, continuously in 28-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly.
Part 2: The recommended phase 2 dose for seviteronel (established in Part 1) once daily along with 0.5 mg dexamethasone, continuously in 21-day cycles with docetaxel 75mg/m2 administered intravenously 3 weekly.
Treatment: Drugs: Seviteronel-D (Seivteronel in combination with dexamethasone)
Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
Treatment: Drugs: Docetaxel
Use of docetaxel chemotherapy for solid tumours
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Recommended phase 2 dose of seviteronel plus dexamethasone and docetaxel
Query!
Assessment method [1]
0
0
A patient will be considered evaluable for dose limiting toxicity (DLT) if they have completed two cycles of docetaxel in an 8-week period with at least 80% of the planned INO-464 dose. Toxicity will be graded using CTCAE version 5.0
Query!
Timepoint [1]
0
0
10 weeks
Query!
Secondary outcome [1]
0
0
Number of patients with treatment-related adverse events
Query!
Assessment method [1]
0
0
Incidence, nature, and severity of adverse events and laboratory abnormalities, with severity determined according to NCI CTCAE v5.0
Query!
Timepoint [1]
0
0
2 years
Query!
Secondary outcome [2]
0
0
Overall response rate (ORR)
Query!
Assessment method [2]
0
0
The proportion of patients with a confirmed complete response or partial response as determined by the investigator according to RECIST v1.1
Query!
Timepoint [2]
0
0
2 years
Query!
Secondary outcome [3]
0
0
Duration of response (DoR)
Query!
Assessment method [3]
0
0
The time from the first occurrence of a documented confirmed complete response or partial response to the first date of recorded disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause (whichever occurs first)
Query!
Timepoint [3]
0
0
2 years
Query!
Secondary outcome [4]
0
0
Overall survival (OS)
Query!
Assessment method [4]
0
0
The time from starting the study treatment to death from any cause
Query!
Timepoint [4]
0
0
2 years
Query!
Eligibility
Key inclusion criteria
- Signed written and voluntary informed consent.
- Patient must be willing and able to comply with scheduled visits, treatment plan,
laboratory tests and other study procedures.
- Age 18 years or older male or female.
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- At least 4 weeks washout period from previous line of treatment, 2 weeks from
radiotherapy
- Adequate haematologic and organ function within 14 days before the first study
treatment on cycle1, day 1
- Life expectancy of at least 3 months
- For women of childbearing potential: agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive methods with a failure rate of <1% per
year during the treatment period and for at least 28 days after the last dose of
seviteronel or, 6 months after the last dose of chemotherapy whichever occurs later.
- Part 1: Histological or cytological-based diagnosis of breast cancer. Any of the three
major subtypes of breast cancer is permitted for the phase 1b study, i.e., hormone
receptor positive breast cancer i.e. oestrogen and/or progesterone positive in greater
than 1% of cells by immunohistochemistry (IHC), or human epidermal growth factor
receptor (HER2) positive breast cancer, i.e., IHC 3+ or in situ hybridisation (ISH)
positive according to standard ASCO/CAP guidelines or triple-negative breast cancer,
i.e., HER2-negative by ASCO/GAO Guidelines and <1% expression of estrogen and/or
progesterone receptor by IHC.
- Part 2: Histological or cytological-based diagnosis of triple-negative breast cancer.
The tumor must be HER2-negative by ASCO/GAO Guidelines and <1% expression of estrogen
and /or progesterone receptor by IHC.
o The tumor must also show androgen receptor positivity (i.e., AR>0%) by IHC or gene
classifier (molecular testing).
- Measurability of lesion: have at least 1 measurable lesion assessable using standard
techniques by RECIST v1.1
- Patients must have advanced or recurrent breast cancer pre-inclusion number 8, for
whom docetaxel is considered an appropriate treatment option.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Inability to comply with study and follow-up procedures.
- History of malabsorption syndrome or other condition that would interfere with enteral
absorption or results in the inability or unwillingness to swallow pills.
- Active infection requiring antibiotics.
- Other invasive malignancy within 2 years except for malignancies determined to have
low recurrence potential in discussion with study PI.
- Known active tuberculosis.
- Female patients who are pregnant or breast-feeding.
- Male or female patients of reproductive potential who are not willing to use effective
birth control from screening to 90 days post treatment.
- Women of childbearing potential (who are not postmenopausal within 12 months of
non-therapy induced amenorrhea, nor surgically sterile) must have a negative serum
pregnancy test result within 3 days prior to initiation of study treatment.
- Uncontrolled intercurrent illness, including psychiatric illness/social situations
that would limit compliance with study requirement, substantially increase risk of
incurring adverse events, or compromise the ability of the subject to give written
informed consent.
- History or current evidence of HIV infection.
- Known clinically significant history of liver disease consistent with Child-Pugh Class
B or C, including active viral or other hepatitis (e.g., positive for hepatitis B
surface antigen [HBsAg] or hepatitis C virus [HCV] antibody at screening), current
drug or alcohol abuse, or cirrhosis:
- Patients with past hepatitis B virus (HBV) infection or resolved HBV infection
(defined as having a negative HBsAg test and a positive antibody to hepatitis B core
antigen antibody test) are eligible.
- Patients positive for HCV antibody are eligible only if polymerase chain reaction is
negative for HCV RNA.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1 of Cycle 1 or anticipation of need for a major surgical procedure
during the course of the study
- Placement of a vascular access device is not considered major surgery.
- Any other disease, metabolic dysfunction, physical examination finding, or clinical
laboratory finding that, in the investigator's opinion, gives reasonable suspicion of
a disease or condition that contraindicates the use of an investigational drug or that
may affect the interpretation of the results or render the patient at high risk from
treatment complications
- Patients with symptomatic central nervous system (CNS) metastasis and/or carcinomatous
meningitis. Patients with treated CNS metastases are eligible for this study if they
are not receiving corticosteroids and/or anticonvulsants for at least 7 days prior to
first dose of study treatment, and their disease is asymptomatic and radiographically
stable for at least 30 days prior to consent by repeat imaging (repeat imaging should
be performed during study screening).
- Unresolved, clinically significant toxicity NCI CTCAE v5.0 grade 2 or higher, from
prior therapy, except for alopecia, endocrinopathy on stable hormonal replacement, and
others as approved by study PI.
- Patients who have received palliative radiation treatment to peripheral sites (e.g.,
bone metastases) for pain control and whose last treatment was completed 14 days prior
to Day 1 of Cycle 1 may be enrolled in the study if they have recovered from all
acute, reversible effects.
- Uncontrolled pleural effusion, pericardial effusion, or ascites.
- Known hypersensitivity or contraindication to any component of the study treatment.
- Administration of any investigational treatment within 30 days or 5 half-lives
(whichever is longer) prior to receiving the first dose of study treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2024
Query!
Actual
Query!
Sample size
Target
65
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Kinghorn Cancer Centre - Darlinghurst
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
St Vincent's Hospital, Sydney
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination
with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04947189
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Rachel F Dear, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61293553633
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04947189
Download to PDF